LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Thermin Skogsbär
Thermin Honung&Citron
(paracetamol)

SE/H/1167/01-02/DC

This module reflects the scientific discussion for the approval of Thermin Skogsbär and Thermin Honung&Citron. The procedure was finalised at 2012-09-26. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

Novartis Sverige AB has applied for a marketing authorisation for Thermin Skogsbär and Thermin Honung&Citron, 500 mg, powder for oral solution, claiming essential similarity to Panodil, 500 mg, powder for oral solution marketed in Sweden by GlaxoSmithKline Consumer Healthcare. The product contains paracetamol as active substance. For approved indications see the Summary of Product Characteristics.

II. QUALITY ASPECTS

II.1 Introduction

Thermin Skogsbär and Thermin Honung&Citron, is presented in the form of powder for oral solution containing 500 mg of paracetamol.

The excipients in Thermin Skogsbär are ascorbic acid (vitamin C), acesulfame potassium, aspartame (E951), calcium phosphate, citric acid, maltodextrin, colloidal hydrated silica, sodium citrate, sucrose, quinoline yellow (E104), blueberry flavour, raspberry flavour, cranberry flavour, menthol flavour, and green tea flavour.

The excipients in Thermin Honung&Citron are ascorbic acid (vitamin C), acesulfame potassium, aspartame (E951), calcium phosphate, citric acid, maltodextrin, colloidal hydrated silica, sodium citrate, sucrose, quinoline yellow (E104) , brilliant blue FCF (E133), allura red AC (E129), lemon flavour, chamomile flavour, honey flavour, and white tea flavour.

The product is packed in unit dose sachet made of polyethylene terephtalate/low density polyethylene/aluminium foil/low density polyethylene heat seal coating.

II.2 Drug Substance

Paracetamol has a monograph in the Ph Eur.

Paracetamol is a white, or almost white, crystalline powder which is sparingly soluble in water, freely soluble in alcohol, very slightly soluble in methylene chloride. The structure of paracetamol has been adequately proven and its physico-chemical properties sufficiently described. The route of synthesis has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The active substance specification includes relevant tests and the limits for impurities/ degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies under ICH conditions have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Medicinal Product

Thermin Skogsbär is formulated using excipients described in the current Ph Eur, except for quinoline yellow, blueberry flavour, raspberry flavour, cranberry flavour, menthol flavour, and green tea flavour which are controlled according to acceptable in house specifications.

Thermin Honung&Citron is formulated using excipients described in the current Ph Eur, except for quinoline yellow, brilliant blue FCF, allura red AC, lemon flavour, chamomile flavour, honey flavour, and white tea flavour which are controlled according to acceptable in house specifications.

All raw materials used in the products are of vegetable origin.

The product development has taken into consideration the physico-chemical characteristics of the active substance.

The manufacturing process has been sufficiently described and critical steps identified. Results from the process validation studies confirm that the process is under control and ensure both batch to batch reproducibility and compliance with the product specification.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies under ICH conditions have been performed and data presented support the shelf life claimed in the SPC, with no special storage precautions.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

An in vivo comparison of the bioavailability between the two test products Thermin Wildberries 500 mg powder for oral solution and Thermin Honey and Lemon 500 mg powder for oral solution versus Panodil 500 mg powder for oral solution has not been performed. According to the Guideline on the investigation of Bioequivalence (CHMP/QWP/EWP/1401/98 Rev. 1), bioequivalence studies may be waived if the test product is an aqueous oral solution at time of administration and contains an active substance in the same concentration as an approved oral solution. However, if the excipients may affect gastrointestinal transit, absorption, solubility or stability, a bioequivalence study should be conducted, unless the difference in these excipients can be adequately justified.

There are several differences in excipients between the applied products and the originator product but these differences are not considered to affect the bioavailability of paracetamol to a clinically relevant extent. Thus no bioequivalence study is considered necessary according to the Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98/ Rev. 1

Corr**).

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

User consultation
The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing the PIL was English.
The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

The risk/benefit ratio is considered positive and Thermin Skogsbär and Thermin Honung&Citron, 500 mg, powder for oral solution is recommended for approval.

VI. APPROVAL

The Decentralised procedure for Thermin Skogsbär and Thermin Honung&Citron, 500 mg, powder for oral solution was successfully finalised on 2012-09-26.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Scope	Procedure number	Product Information affected	Date of start of the procedure	Date of end of procedure	Approval/ non approval	Assessment report attached
						Y/N (version)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se